Immunocore Holdings (IMCR) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.28

Estimate

-$0.14

Surprise

-107.3%

Revenue (period 2026-09-30)

$102.2M

Score today

5.7/10

Revenue source: xbrl.

Immunocore Holdings (IMCR) reported a wider loss than forecast — adjusted EPS of -$0.28 against the -$0.14 estimate (a 107.3% shortfall).

• Immunocore Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-06
• Immunocore Presents Phase 1/2 Data for Brenetafusp Combination Therapy — fiscal.ai, 2026-11-06
• Immunocore Holdings Announces Data Form Its Phase 1/2 Study Of Brenetafusp Shows 29% Overall Response Rate, 71% Disease — benzinga, 2026-11-06

TrendMatrix currently rates IMCR Sell at 5.7/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -107.3% surprise compares with a -75.6% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$30.99

Price target

$52.90

Stop

$28.82

Upside to target

+70.7%

Reward-to-risk

6.3:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.60B

P/E (fwd)

-32.2

52-week range

$27.50–$40.72

Off 52-week high

23.9%

RSI (14)

54

Volume vs avg

2.75×

Score today

5.7/10